Nail · Fingernail onychomycosis
Onychomycosis laser evidence for Fingernail onychomycosis
There is a relatively good level of clinical evidence, and a majority of papers support its effectiveness.
Grade combines the quantity and quality of the research, while direction is a separate signal showing how the papers assess effectiveness.
Includes meta-analysis/SR Median year 2001 Last 5 years 12% Positive results 47% Negative results 4 Korea/Asia 3
Known in Korea as
Procedure and brand names vary, but the evidence above applies to the same procedure mechanism.
Key papers
tier1 Combined fractional CO2 laser with topical tioconazole versus Q-switched Nd-YAG laser in the treatment of onychomycosis; a randomized comparative trial.
Abstract summary (English) Treatment of onychomycosis includes topical and systemic agents. However, prolonged use of oral treatment could cause adverse effects and topical antifungal agents have limited penetration. To compare the clinical efficacy and the safety of fractional CO2 laser combined with topical tioconazole nail solution versus Q-switched 1064 Nd: YAG laser in the treatment of fingernail onychomycosis.
Journal Article, Randomized Controlled Trial, Comparative Study
View on PubMedtier1 Understanding Global Access to Topical Onychomycosis Therapy: A Systematic Review and Meta-Analysis.
Abstract summary (English) INTRODUCTION: Equal access to medicines is crucial to ensuring public health, but access is difficult to measure, especially for infections where changes in infective species make treatment choices highly dynamic. This study investigated if the combination of infection prevalence with medicine efficacy and regulatory availability could access medicines access of topical onychomycosis medicines. METHODS: Two...
Journal Article, Meta-Analysis, Systematic Review
View on PubMedtier1 Comparative study of safety and efficacy of combination therapy of fractional CO2 laser and topical amorolfine cream versus oral itraconazole in the treatment of onychomycosis.
Abstract summary (English) Onychomycosis is a fungal infection of the nail unit caused by various species of dermatophytes, non-dermatophytic moulds or yeasts. They pose a therapeutic challenge to the treating dermatologist as the infection is often resistant to treatment and requires prolonged therapy. To evaluate the efficacy and safety profile of fractional CO2 laser and 0.25% Amorolfine hydrochloride cream in the treatment of...
Randomized Controlled Trial, Journal Article
View on PubMedtier1 Effect of onychomycosis and treatment on patient-reported quality-of-life outcomes: A systematic review.
Abstract summary (English) BACKGROUND: Onychomycosis is the most common nail disorder, often causing physical, emotional, and aesthetic consequences. The effect of both the condition itself and treatment on quality of life has not been well studied. OBJECTIVE: The objectives of this study were to systematically review the available literature describing the effect of onychomycosis and treatment on quality of life.
Journal Article, Systematic Review
View on PubMedtier1 A randomized trial of amorolfine 5% solution nail lacquer in association with itraconazole pulse therapy compared with itraconazole alone in the treatment of Candida fingernail onychomycosis.
Abstract summary (English) BACKGROUND: Treatment failures and relapses are not uncommon in onychomycosis. Therefore, it is worthwhile to consider the combination of systemic and topical antifungals to improve the cure rates further and to reduce the duration of systemic treatment. OBJECTIVES: To evaluate and compare itraconazole pulse therapy combined with amorolfine with itraconazole alone in the treatment of Candida fingernail onychomycosis.
Clinical Trial, Journal Article, Randomized Controlled Trial
View on PubMedtier1 Economic analysis of oral and topical therapies for onychomycosis of the toenails and fingernails.
Abstract summary (English) OBJECTIVE: Several antifungal agents are indicated for onychomycosis, a fungal infection of the toenails and fingernails. These agents differ in their dosing regimen, efficacy, adverse events profile, potential for drug interaction, and cost. We conducted a pharmacoeconomic analysis of oral and topical therapies for onychomycosis from the perspective of a hypothetical managed care payer to determine the most...
Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't
View on PubMedtier1 A comparison among four regimens of itraconazole treatment in onychomycosis.
Abstract summary (English) The purpose of this study was to compare the efficacy of different dosage regimens in the management of onychomycosis with itraconazole and to determine the results of a further 1-week intermittent pulse treatment in non-cured patients. In this study, 153 patients were randomly allocated to four groups. Patients in group A were treated with daily doses of 100 mg for 3 months in the case of fingernail onychomycosis...
Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial
View on PubMedtier1 Continuous and intermittent itraconazole dosing schedules for the treatment of onychomycosis: a pharmacokinetic comparison.
Abstract summary (English) This multicentre, double-blind, randomized study compared the pharmacokinetics of itraconazole given at 200 mg once daily for 3 months and intermittently at 200 mg twice daily for 1 week per month followed by a 3-week drug-free period for 3 months in the treatment of onychomycosis. Patients were followed for 9 months after treatment. Itraconazole and hydroxy-itraconazole plasma concentrations and itraconazole nail...
Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
View on PubMedtier1 Pharmacokinetics of three once-weekly dosages of fluconazole (150, 300, or 450 mg) in distal subungual onychomycosis of the fingernail.
Abstract summary (English) BACKGROUND: Fluconazole has proven to be safe and effective for a variety of superficial and systemic fungal infections. Preliminary analysis of extensive Phase III studies suggests that it is very effective for the treatment of onychomycosis. Its pharmacokinetic properties, including low molecular weight and high water-solubility, suggest a unique ability to penetrate the nail.
Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
View on PubMedtier1 Once-weekly fluconazole (150, 300, or 450 mg) in the treatment of distal subungual onychomycosis of the fingernail.
Abstract summary (English) BACKGROUND: Onychomycosis is a prevalent infection of the nail caused primarily by dermatophytes. Fluconazole is active in vitro against the most common pathogens, penetrates into the nail bed, and is clinically effective in the treatment of a wide variety of fungal infections. OBJECTIVE: The purpose of this study was to assess the safety and efficacy of oral fluconazole 150, 300, and 450 mg administered once weekly...
Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
View on PubMedPersonalized evidence report
Tell us more about your concern
and the Glass Lab bot will build a personalized report for you.
Based on the Onychomycosis laser · Fingernail onychomycosis information on this page, we'll email you an evidence summary tailored to your skin condition and treatment stage.